Skip to content


  • Research Article
  • Open Access

Synthesis, biological evaluation and molecular docking studies of 6-(4-nitrophenoxy)-1H-imidazo[4,5-b]pyridine derivatives as novel antitubercular agents: future DprE1 inhibitors

Chemistry Central Journal201812:138

  • Received: 12 November 2018
  • Accepted: 6 December 2018
  • Published:


Tuberculosis is an air-borne disease, mostly affecting young adults in their productive years. Here, Ligand-based drug design approach yielded a series of 23 novel 6-(4-nitrophenoxy)-1H-imidazo[4,5-b]pyridine derivatives. The required building block of imidazopyridine was synthesized from commercially available 5,5-diaminopyridine-3-ol followed by four step sequence. Derivatives were prepared using various substituted aromatic aldehydes. All the synthesized analogues were characterized using NMR, Mass analysis and also screened for in vitro antitubercular activity against Mycobacterium tuberculosis (H37Rv). Four compounds, 5c (MIC-0.6 μmol/L); 5g (MIC-0.5 μmol/L); 5i (MIC-0.8 μmol/L); and 5u (MIC-0.7 μmol/L) were identified as potent analogues. Drug receptor interactions were studied with the help of ligand docking using maestro molecular modeling interphase, Schrodinger. Here, computational studies showed promising interaction with other residues with good score, which is novel finding than previously reported. So, these compounds may exhibit in vivo DprE1 inhibitory activity.
Graphical Abstract image


  • Tuberculosis
  • Imidazopyridine derivatives
  • DprE1 inhibitors
  • Antitubercular activity


Tuberculosis is major threat for mankind from past several decades. Tuberculosis is the leading cause of death from infectious diseases [1]. Although the number of tuberculosis cases decreased during the twentieth century, the emergence of HIV and the incidence of multiple-drug resistance (MDR) have increased the difficulty of treating many new cases. Despite of the efforts taken to improve the outcome of tuberculosis care, the discovery of new antibiotics against the causative agent is not in a race of expected progress [2, 3]. With this, new and more effective molecules with novel mechanism of action are required to discover which may shorten the treatment, improve patient adherence, and reduce the appearance of resistance [4].

Furthermore, Mycobacterium tuberculosis (M. tuberculosis) has also proven one of the world’s most dreadful human pathogen because of its ability to persist inside humans for longer time period in a clinically inactive state. Roughly 95% of the general population who infected (33% of the worldwide population) built up an inert infection [5, 6]. The current available vaccine, Mycobacterium bovis Bacillus Calmette–Guerin (BCG). M. tuberculosis stimulates a solid response, however it has ability to oppose the body’s activities to kill it and regardless of the possibility of underlying disease is effectively controlled. The discovery of drugs with novel mechanism of action is required because of the expanding number of MDR, which are strains of M. tuberculosis that are resistant to both isoniazid and rifampicin (first line therapy), with or without protection from different medications, broadly extensively drug resistance (XDR) and MDR strains additionally resistant to any fluoroquinolone and any of the second-line against TB injectable medications (amikacin, kanamycin, or capreomycin). Imidazopyridine derivatives are very important, versatile motifs with significant applications in medicinal chemistry [79].

The imidazopyridine scaffold was found in a number of marketed drug formulations and drug candidates such as antiulcer-zolimidine [10] and tenatoprazole [1113], sedative-zolpidem [14], anxiolytic-saripidem [15] and necopidem [16, 17], analgesic and antipyretic-microprofen [18], cardiotonic-olprinone [19, 20], anti-tumour-3-deazaneplanocin A [21, 22]. Fortunately, 3-deazaneplanocin A was also found to be effective for the treatment against Ebola virus disease [2326]. In addition, compounds containing the moiety imidazopyridine have significant biological applications such as antimycobacterial, anticoccidial, antimicrobial [2734].

In other words, the therapeutic application of imidazopyridine is not restricted, and need to explore to the fullest for the betterment of mankind. Here, we are looking forward to uncover the potential of 1H-imidazo[4,5-b]pyridine nucleus as a biological agent, hence, we thought to synthesize 6-(4-nitrophenoxy)-2-substituted-1H-imidazo[4,5-b]pyridine derivatives. Purposely 4-nitrophenoxy substitution was chosen on 6th position of 1H-imidazo[4,5-b]pyridine ring because it was proved that the nitro containing compounds shown binding with cys387 residue of DprE1 enzyme protein.

Reports of World Health Organisation (WHO) in past couple of years pointed out that, the global burden of tuberculosis is increasing drastically across the globe. With this threatening scenario of tuberculosis infection, it’s a strict need to search promising drugs which will effectively kill the mycobacterium within short duration of time. Here, we have made an attempt to synthesized novel compounds of imidazopyridine series for antitubercular activity, which may target particularly decaprenyl-phosphoryl-ribose 2′-epimerase (DprE1) enzyme (DprE1 is a novel target for which no drug is available in market till date) in search of novel lead for antitubercular drug discovery to serve the society.



All the chemicals were obtained from Sigma Aldrich, Germany, Merk India, Rankem India, Loba Chemi, India, Signichem laboratories, India. Melting points (m.p.) were detected with open capillaries using Veego Melting point apparatus, Mumbai India and are uncorrected. IR spectra were recorded on IR Affinity-1S (FTIR, Schimadzu, Japan) spectrophotometer. 1H and 13C NMR was obtained using a JEOL, JAPAN ECZR Series 600 MHz NMR Spectrometer using tetramethylsilane (TMS) as internal standard. All chemical shift values were recorded as δ (ppm), coupling constant value J was measured in hertz, the peaks are presented as s (singlet), d (doublet), t (triplet), dd (double doublet), m (multiplet). The purity of compounds was controlled by thin layer chromatography (Qualigens Fine Chemicals Mumbai, silica gel, GF-254).

General procedure for synthesis

5,6-Diaminopyridine-3-ol and different substituted aromatic aldehydes were commercially available. The process of four step reaction sequence was initiated with acetylation of 5,6-diaminopyridine-3-ol 1 which on reaction with acetic anhydride forms compound 2 by nucleophilic substitution reaction [35]. To increase the reactivity of –OH, the hydroxyl group, it is converted to its potassium salt by stirring compound 2 [36] with K2CO3 in dimethylformamide (DMF) for 3–4 h and then, p-chloronitrobenzene diluted in DMF (1:1) was added drop-wise for 1 h [37]. Again reaction mixture was stirred for 2–3 h to obtained compound 3. Further, the reactions mixture was poured in cold 10% sodium hydroxide [38, 39]. The compound 4 was precipitated out which further recrystallized by ethanol [40, 41]. Compound 4 on reaction with different substituted aromatic aldehydes (Table 1) in presence of Na2S2O5 yielded compound 5 derivatives (Scheme 1).
Table 1

Synthesis of compounds from 5a–w

Scheme 1
Scheme 1

Synthesis of 6-(4-nitrophenoxy)-1H-imidazo[4,5-b]pyridine derivatives

1: 5,6-diaminopyridine-3-ol. IR v = 1390 cm−1 (C–N str), 1780 cm−1 (aromatic ring), 3320 cm−1 (O–H str), 1H NMR: (600 MHz, DMSO) δ 6.4 (1H, d, J = 2.7 Hz), 7.7 (1H, d, J = 2.7 Hz).13C NMR (100 MHz, DMSO) δ (ppm) 100.9, 135.2, 140.4, 153.2. MS m/z: calcd for C5H7N3O found 125.13 (M–H): 124.61.

2: N-(3-acetamido-5-hydroxypyridin-2-yl)acetamide. IR v = 1670 cm−1 (C–O str), 1670 cm−1 (aromatic ring), 3420 cm−1 (O–H str), 1H NMR: (600 MHz, DMSO) δ 2.7–2.9 (6H, m), 7.2 (1H, d, J = 2.3 Hz), 7.8 (1H, d, J = 2.3 Hz).13C NMR (100 MHz, DMSO) δ (ppm) 23.9, 100.9, 121.7, 135.2, 142.5, 153.2, 168.7. MS m/z: calcd for C9H11N3O3 found 209.20 (M–H): 208.65.

4: 5-(4-nitrophenoxy)pyridine-2,3-diamine. IR v = 1540 cm−1 (N–O str), 1680 cm−1 (C–O ether), 1530, 1620 cm−1 (aromatic ring), 1440 cm−1 (C–N str), 1H NMR: (600 MHz, DMSO) δ 6.8 (1H, d, J = 2.8 Hz), 7.2–7.3 (4H, m), 7.8 (1H, d, J = 2.8 Hz).13C NMR (100 MHz, DMSO) δ (ppm) 100.9, 116.9, 124.5, 135.2, 140.4, 143.2, 151.5, 163.8. MS m/z: calcd for C11H12N4O3 found 248.23 (M–H): 247.63.

5a: 4-[6-(4-nitrophenoxy)-1H-imidazo[4,5-b]pyridin-2-yl]benzene-1,2-diol. Yield: 32%. M.P. 140 °C–142 °C. IR v = 1540 cm−1 (N–O str), 1150 cm−1 (C–O ether), 1480, 1550, 1690, 1740 cm−1 (aromatic ring), 3470 cm−1 (O–H str), 1H NMR: (600 MHz, DMSO) δ 4.0 (2H, s), 6.9 (1H, dd, J = 8.9, 0.4 Hz), 7.2 (2H, dd, J = 8.4, 1.5 Hz), 7.3 (1H, d, J = 1.8 Hz), 7.4 (1H, dd, J = 8.9, 1.8 Hz), 7.9 (1H, d, J = 1.6 Hz), 8.0 (2H, dd, J = 8.4, 1.9 Hz), 8.6 (1H, d, J = 1.6 Hz).13C NMR (100 MHz, DMSO) δ (ppm) 40.4, 115.3, 119.7, 123.5, 126.8, 130.1, 137.8, 145.3, 146.6, 151.2. MS m/z: calcd for C18H12N4O5 found 364.08 (M–H): 363.53.

5b: 5-fluoro-2-[6-(4-nitrophenoxy)-1H-imidazo[4,5-b]pyridin-2-yl]phenol. Yield: 45%. M.P. 157 °C–159 °C. IR v = 1420 cm−1 (N–O str), 1190 cm−1 (C–O ether), 1430, 1540, 1890 cm−1 (aromatic ring), 3220 cm−1 (O–H str), 1H NMR: (600 MHz, DMSO) δ 4.0 (2H, s), 6.3 (1H, d, J = 1.6 Hz), 6.4 (1H, dd, J = 8.5, 1.6 Hz), 7.2 (2H, dd, J = 8.5, 1.5 Hz), 7.6 (1H, d, J = 8.5 Hz), 7.9 (1H, d, J = 1.6 Hz), 8.0 (2H, dd, J = 8.5, 1.9 Hz), 8.7 (1H, d, J = 1.6 Hz).13C NMR (100 MHz, DMSO) δ (ppm) 40.4, 100.5, 113.4, 117.2, 127.8, 140.4, 148.9, 158.7, 162.2. MS m/z: calcd for C18H11FN4O4 found 366.07 (M–H): 365.37.

5c: 3-[6-(4-nitrophenoxy)-1H-imidazo[4,5-b]pyridin-2-yl]benzene-1,2-diol. Yield: 30%. M.P. 148 °C–150 °C. IR v = 1380 cm−1 (N–O str), 1120 cm−1 (C–O ether), 1490, 1630, 1770 cm−1 (aromatic ring), 3360 cm−1 (O–H str), 1H NMR: (600 MHz, DMSO) δ 4.0 (2H, s), 6.9 (1H, dd, J = 8.0, 1.3 Hz), 7.1–7.3 (3H, m), 7.3 (1H, dd, J = 7.8, 1.3 Hz), 7.9 (1H, d, J = 1.6 Hz), 8.0 (2H, dd, J = 8.4, 1.9 Hz), 8.6 (1H, d, J = 1.6 Hz). 13C NMR (100 MHz, DMSO) δ (ppm) 40.4, 115.6, 126.3, 137.8, 145.2, 146.5, 152.3. MS m/z: calcd for C18H12N4O5 found 364.09 (M–H): 363.49.

5d: 4-bromo-3-[6-(4-nitrophenoxy)-1H-imidazo[4,5-b]pyridin-2-yl]phenol. Yield: 49%. M.P. 135 °C–137 °C. IR v = 1470 cm−1 (N–O str), 1140 cm−1 (C–O ether), 1580, 1630, 1850 cm−1 (aromatic ring), 3320 cm−1 (O–H str), 1H NMR: (600 MHz, DMSO) δ 4.0 (2H, s), 6.9 (1H, d, J = 8.2 Hz), 7.0 (1H, dd, J = 8.2, 2.7 Hz), 7.2 (2H, dd, J = 8.4, 1.5 Hz), 7.3 (1H, d, J = 2.7 Hz), 7.9 (1H, d, J = 1.6 Hz), 8.0 (2H, dd, J = 8.4, 1.9 Hz), 8.6 (1H, d, J = 1.6 Hz). 13C NMR (100 MHz, DMSO) δ (ppm) 40.4, 115.6, 129.9, 138.6, 148.9, 158.7. MS m/z: calcd for C18H11BrN4O4 found 427.21 (M–H): 426.65.

5e: 2-(2-chlorophenyl)-6-(4-nitrophenoxy)-1H-imidazo[4,5-b]pyridine. Yield: 52%. M.P. 152 °C–154 °C. IR v = 1420 cm−1 (N–O str), 1160 cm−1 (C–O ether), 1620, 1740, 1730 cm−1 (aromatic ring), 3420 cm−1 (O–H str) 1H NMR: (600 MHz, DMSO) δ 4.1 (2H, s), 7.1 (1H, d, J = 8.1 Hz), 7.2-7.4 (3H, m), 7.9 (1H, dd, J = 7.6, 1.7 Hz), 8.0–8.7 (3H, m), 8.7 (1H, d, J = 1.6 Hz). 13C NMR (75 MHz, DMSO) δ (ppm) 40.4, 113.4, 126.8, 140.4, 158.7. MS m/z: calcd for C18H11ClN4O3 found 366.76 (M–H): 365.57.

5f: 2-(2-fluorophenyl)-6-(4-nitrophenoxy)-1H-imidazo[4,5-b]pyridine. Yield: 43%. M.P. 137 °C–139 °C. IR v = 1370 cm−1 (N–O str), 1190 cm−1 (C–O ether), 1710, 1770, 1780 cm−1 (aromatic ring), 3450 cm−1 (O–H str) 1H NMR: (600 MHz, DMSO) δ 7.2–7.5 (3H, m), 7.3–7.5 (2H, m), 7.6 (1H, d, J = 1.7 Hz), 7.9 (1H, dd, J = 7.6, 1.7 Hz), 8.1 (2H, dd, J = 8.3, 2.1 Hz), 8.4 (1H, d, J = 1.7 Hz). 13C NMR (100 MHz, DMSO) δ (ppm) 100.9, 114.2, 127.5, 140.4, 152.3, 156.0, 160.4. MS m/z: calcd for C18H11FN4O3 found 350.09 (M–H): 349.57.

5g: 2-(2,6-dimethoxyphenyl)-6-(4-nitrophenoxy)-1H-imidazo[4,5-b]pyridine. Yield: 46%. M.P. 128 °C–130 °C. IR v = 1510 cm−1 (N–O str), 1120 cm−1 (C–O ether), 1650, 1760, 1660 cm−1 (aromatic ring), 3520 cm−1 (O–H str) 1H NMR: (600 MHz, DMSO) δ 3.8 (6H, s), 6.9 (2H, dd, J = 8.1, 1.2 Hz), 7.3 (2H, dd, J = 8.4, 1.3 Hz), 7.4–7.5 (2H, m), 8.1 (2H, dd, J = 8.3, 2.1 Hz), 8.2 (1H, d, J = 1.7 Hz). 13C NMR (100 MHz, DMSO) δ (ppm) 55.8, 100.9, 117.2, 130.6, 140.4, 151.2, 156.0. MS m/z: calcd for C20H16N4O5 found 392.12 (M–H): 391.56.

5h: 6-(4-nitrophenoxy)-2-(4-nitrophenyl)-1H-imidazo[4,5-b]pyridine. Yield: 26%. M.P. 164 °C–166 °C. IR v = 1360 cm−1 (N–O str), 1175 cm−1 (C–O ether), 1750, 1770, 1790 cm−1 (aromatic ring), 3130 cm−1 (O–H str) 1H NMR: (600 MHz, DMSO) δ 7.3 (2H, dd, J = 8.4, 1.4 Hz), 7.8 (1H, d, J = 1.6 Hz), 7.9 (2H, dd, J = 8.8, 1.6 Hz), 8.1–8.2 (4H, m), 8.7 (1H, d, J = 1.6 Hz). 13C NMR (100 MHz, DMSO) δ (ppm) 100.9, 115.0, 126.1, 135.2, 145.4, 156.0. MS m/z: calcd for C18H11N5O5 found 377.09 (M–H): 376.47.

5i: 6-(4-nitrophenoxy)-2-(3-nitrophenyl)-1H-imidazo[4,5-b]pyridine Yield: 29%. M.P. 149 °C–151 °C. IR v = 1380 cm−1 (N–O str), 1160 cm−1 (C–O ether), 1610, 1720, 1770 cm−1 (aromatic ring), 3490 cm−1 (O–H str) 1H NMR: (600 MHz, DMSO) δ 7.3 (2H, dd, J = 8.4, 1.4 Hz), 7.6 (1H, dd, J = 8.7, 7.6 Hz), 7.8 (1H, d, J = 1.6 Hz), 8.0 (1H, dd, J = 7.9, 1.6 Hz), 8.1–8.2 (4H, m) 8.7 (1H, d, J = 1.6 Hz). 13C NMR (100 MHz, DMSO) δ (ppm) 100.9, 117.2, 126.9, 140.4, 156.0. MS m/z: calcd for C18H11N5O5 found 377.20 (M–H): 376.59.

5j: 2-(2-bromophenyl)-6-(4-nitrophenoxy)-1H-imidazo[4,5-b]pyridine. Yield: 33%. M.P. 170 °C–172 °C. IR v = 1490 cm−1 (N–O str), 1230 cm−1 (C–O ether), 1680, 1710, 1820 cm−1 (aromatic ring), 3300 cm−1 (O–H str) 1H NMR: (600 MHz, DMSO) δ 7.3 (2H, dd J = 8.3, 1.2 Hz), 7.3–7.5 (2H, m), 7.6 (1H, d, J = 1.7 Hz), 7.7 (1H, dd, J = 7.9, 1.1 Hz), 7.9 (1H, dd, J = 7.6, 1.6 Hz), 8.1 (2H, dd, J = 8.3, 2.1 Hz), 8.4 (1H, d, J = 1.7 Hz). 13C NMR (100 MHz, DMSO) δ (ppm) 100.9, 112.5, 126.3, 140.4, 156.0. MS m/z: calcd for C18H11BrN4O3 found 410.01 (M–H): 409.43.

5k: 2-(4-chlorophenyl)-6-(4-nitrophenoxy)-1H-imidazo[4,5-b]pyridine. Yield: 30%. M.P. 142 °C–144 °C. IR v = 1380 cm−1 (N–O str), 1180 cm−1 (C–O ether), 1690, 1850, 1730 cm−1 (aromatic ring), 3230 cm−1 (O–H str) 1H NMR: (600 MHz, DMSO) δ 7.3 (2H, dd, J = 8.3, 1.2 Hz), 7.6 (1H, d, J = 1.6 Hz), 7.7–7.8 (4H, m), 8.1 (2H, dd, J = 8.3, 2.1 Hz), 8.4 (1H, d, J = 1.6 Hz). 13C NMR (100 MHz, DMSO) δ (ppm) 100.9, 115.0, 128.0, 135.2, 151.2, 156.0. MS m/z: calcd for C18H11ClN4O3 found 366.05 (M–H): 365.04.

5l: 2-(4-methylphenyl)-6-(4-nitrophenoxy)-1H-imidazo[4,5-b]pyridine. Yield: 32%. M.P. 160 °C–162 °C. IR v = 1350 cm−1 (N–O str), 1240 cm−1 (C–O ether), 1650, 1710, 1810 cm−1 (aromatic ring), 3140 cm−1 (O–H str) 1H NMR: (600 MHz, DMSO) δ 2.3 (3H, s), 7.2–7.3 (4H, m), 7.66 (1H, d, J = 1.8 Hz), 7.9 (2H, dd, J = 7.9, 1.6 Hz), 8.1–8.1 (3H, m). 13C NMR (100 MHz, DMSO) δ (ppm) 100.9, 115.0, 129.3, 139.7, 140.4, 151.2, 156.0. MS m/z: calcd for C19H14N4O3 found 346.10 (M–H): 345.57.

5m: 5-methyl-2-[6-(4-nitrophenoxy)-1H-imidazo[4,5-b]pyridin-2-yl]phenol Yield: 28%. M.P. 142 °C–144 °C. IR v = 1410 cm−1 (N–O str), 1120 cm−1 (C–O ether), 1630, 1710, 1720 cm−1 (aromatic ring), 3410 cm−1 (O–H str) 1H NMR: (600 MHz, DMSO) δ 2.2 (3H, s), 7.2–7.2 (2H, m), 7.3 (2H, dd, J = 8.3, 1.2 Hz), 7.6 (1H, d, J = 1.7 Hz), 7.6 (1H, dd, J = 8.1 Hz), 8.1 (1H, d, J = 1.7 Hz), 8.1 (2H, dd, J = 8.3, 2.1 Hz). 13C NMR (100 MHz, DMSO) δ (ppm) 21.4, 100.9, 115.8, 127.8, 140.4, 152.3, 158.7. MS m/z: calcd for C19H14N4O4 found 362.10 (M–H): 361.15.

5n: 2-(2-methylphenyl)-6-(4-nitrophenoxy)-1H-imidazo[4,5-b]pyridine. Yield: 41%. M.P. 135 °C–137 °C. IR v = 1450 cm−1 (N–O str), 1140 cm−1 (C–O ether), 1730, 1810, 1730 cm−1 (aromatic ring), 3120 cm−1 (O–H str) 1H NMR: (600 MHz, DMSO) δ 2.2 (3H, s), 7.3 (2H, dd, J = 8.4, 1.2 Hz), 7.3 (1H, dd, J = 7.9, 1.1 Hz), 7.4–7.6 (2H, m), 7.6 (1H, d, J = 1.8 Hz), 7.7 (1H, dd, J = 7.7, 1.6 Hz), 8.1–8.1 (3H, m). 13C NMR (100 MHz, DMSO) δ (ppm) 19.8, 100.9, 124.4, 130.7, 140.4, 151.2, 156.0. MS m/z: calcd for C19H14N4O3 found 346.10 (M–H): 345.47.

5o: 2-(3-bromophenyl)-6-(4-nitrophenoxy)-1H-imidazo[4,5-b]pyridine. Yield: 30%. M.P. 166 °C–168 °C. IR v = 1490 cm−1 (N–O str), 1190 cm−1 (C–O ether), 1660, 1720, 1740 cm−1 (aromatic ring), 3340 cm−1 (O–H str) 1H NMR: (600 MHz, DMSO) δ 7.3 (2H, dd, J = 8.3, 1.2 Hz), 7.4 (1H, td, J = 8.0 Hz), 7.5 (1H, dd, J = 8.0, 1.6 Hz), 7.6 (1H, dd, J = 8.0, 1.5 Hz), 7.7 (1H, d, J = 1.6 Hz), 8.0 (1H, s, J = 1.5 Hz), 8.1 (2H, dd, J = 8.3, 2.1 Hz), 8.4 (1H, d, J = 1.6 Hz) 13C NMR (100 MHz, DMSO) δ (ppm) 100.9, 126.8, 135.2, 140.4, 151.5, 156.0. MS m/z: calcd for C18H11BrN4O3 found 410.0 (M–H): 409.45.

5p: 2-(3-methylphenyl)-6-(4-nitrophenoxy)-1H-imidazo[4,5-b]pyridine. Yield: 34%. M.P. 148 °C–150 °C. IR v = 1470 cm−1 (N–O str), 1250 cm−1 (C–O ether), 1670, 1750, 1860 cm−1 (aromatic ring), 3560 cm−1 (O–H str) 1H NMR: (600 MHz, DMSO) δ 2.2 (3H, s), 7.2–7.3 (3H, m), 7.5 (1H, dd, J = 7.9, 7.7 Hz), 7.6–7.7 (2H, m), 7.9 (1H, dd, J = 1.6, 1.5 Hz), 8.1–8.2 (3H, m). 13C NMR (100 MHz, DMSO) δ (ppm) 20.9, 100.9, 119.7, 135.2, 151.2, 151.5, 156.0. MS m/z: calcd for C19H14N4O3 found 346.10 (M–H): 345.50.

5q: 2-(3-methylphenyl)-6-(4-nitrophenoxy)-1H-imidazo[4,5-b]pyridine. Yield: 40%. M.P. 171 °C–173 °C. IR v = 1330 cm−1 (N–O str), 1160 cm−1 (C–O ether), 1680, 1650, 1820 cm−1 (aromatic ring), 3340 cm−1 (O–H str) 1H NMR: (600 MHz, DMSO) δ 2.2 (3H, s), 7.2–7.4 (3H, m), 7.4 (1H, dd, J = 7.9, 7.7 Hz), 7.6–7.6 (2H, m), 7.9 (1H, s, J = 1.5 Hz), 8.1–8.2 (3H, m). 13C NMR (100 MHz, DMSO) δ (ppm) 20.9, 100.9, 117.2, 128.4, 130.4, 140.4, 151.5, 156.0. MS m/z: calcd for C19H14N4O3 found 346.10 (M–H): 345.41.

5r: 5-methoxy-2-[6-(4-nitrophenoxy)-1H-imidazo[4,5-b]pyridin-2-yl]phenol Yield: 31%. M.P. 144 °C–146 °C. IR v = 1370 cm−1 (N–O str), 1260 cm−1 (C–O ether), 1720, 1710, 1690 cm−1 (aromatic ring), 3310 cm−1 (O–H str) 1H NMR: (600 MHz, DMSO) δ 3.8 (3H, s), 6.5 (1H, d, J = 1.6 Hz), 7.0 (1H, dd, J = 8.4, 1.6 Hz), 7.3 (2H, dd, J = 8.3, 1.3 Hz), 7.5–7.5 (2H, m), 8.1 (2H, dd, J = 8.3, 2.1 Hz), 8.3 (1H, d, J = 1.7 Hz). 13C NMR (100 MHz, DMSO) δ (ppm) 55.4, 100.6, 117.2, 135.2, 156.0, 161.8. MS m/z: calcd for C19H14N4O5 found 378.09 (M–H): 377.52.

5s: 2-(3,4-dimethoxyphenyl)-6-(4-nitrophenoxy)-1H-imidazo[4,5-b]pyridine. Yield: 38%. M.P. 166 °C–167 °C. IR v = 1350 cm−1 (N–O str), 1130 cm−1 (C–O ether), 1655, 1690, 1710 cm−1 (aromatic ring), 3320 cm−1 (O–H str) 1H NMR: (600 MHz, DMSO) δ 3.7 (3H, s), 3.8 (3H, s), 6.5 (1H, d, J = 6.2 Hz), 7.3 (2H, dd, J = 8.4, 1.4 Hz), 7.4 (1H, d, J = 1.7 Hz), 8.0 (1H, d, J = 1.7 Hz), 8.1 (2H, dd, J = 8.3, 2.1 Hz). 13C NMR (100 MHz, DMSO) δ (ppm) 56.1, 111.0, 119.7, 128.2, 140.4, 152.3, 156.0. MS m/z: calcd for C20H16N4O5 found 392.11 (M–H): 391.53.

5t: 2-(3-chlorophenyl)-6-(4-nitrophenoxy)-1H-imidazo[4,5-b]pyridine. Yield: 26%. M.P. 158 °C–160 °C. IR v = 1380 cm−1 (N–O str), 1220 cm−1 (C–O ether), 1665, 1780, 1670 cm−1 (aromatic ring), 3540 cm−1 (O–H str) 1H NMR: (600 MHz, DMSO) δ 7.3 (2H, dd, J = 8.3, 1.2 Hz), 7.4–7.5 (2H, m), 7.6 (1H, dd, J = 8.0, 1.6 Hz), 7.7 (1H, d, J = 1.6 Hz), 7.8 (1H, s, J = 1.5 Hz), 8.1 (2H, dd, J = 8.3, 2.1 Hz), 8.4 (1H, d, J = 1.6 Hz). 13C NMR (100 MHz, DMSO) δ (ppm) 100.9, 119.7, 126.8, 129.5, 151.7, 156.0. MS m/z: calcd for C18H11ClN4O3 found 366.05 (M–H): 365.55.

5u: 2-(3-bromophenyl)-6-(4-nitrophenoxy)-1H-imidazo[4,5-b]pyridine. Yield: 41%. M.P. 160 °C–162 °C. IR v = 1330 cm−1 (N–O str), 1280 cm−1 (C–O ether), 1620, 1830, 1790 cm−1 (aromatic ring), 3130 cm−1 (O–H str) 1H NMR: (600 MHz, DMSO) δ 7.3 (2H, dd, J = 8.3, 1.2 Hz), 7.6 (1H, d, J = 1.7 Hz), 7.7 (2H, dd, J = 8.2, 1.6 Hz), 7.8 (2H, dd, J = 8.2, 1.6 Hz), 8.1 (2H, dd, J = 8.3, 2.1 Hz), 8.4 (1H, d, J = 1.7 Hz). 13C NMR (100 MHz, DMSO) δ (ppm) 100.9, 119.7, 128.3, 135.2, 151.2, 156.0. MS m/z: calcd for C18H11BrN4O3 found 410.0 (M–H): 409.46.

5v: 6-(4-nitrophenoxy)-2-(3-nitrophenyl)-1H-imidazo[4,5-b]pyridine. Yield: 32%. M.P. 128 °C–130 °C. IR v = 1340 cm−1 (N–O str), 1240 cm−1 (C–O ether), 1680, 1840, 1770 cm−1 (aromatic ring), 3210 cm−1 (O–H str) 1H NMR: (600 MHz, DMSO) δ 7.3 (2H, dd, J = 8.4, 1.4 Hz), 7.6 (1H, dd, J = 8.6, 8.0 Hz), 7.7 (1H, d, J = 1.6 Hz), 8.1 (2H, dd, J = 8.4, 2.1 Hz), 8.3 (1H, dd, J = 8.0, 1.9 Hz), 8.5 (1H, dd, J = 8.6, 1.9 Hz), 8.6 (1H, d, J = 1.6 Hz), 8.9 (1H, dd, J = 1.6, 1.5 Hz). 13C NMR (100 MHz, DMSO) δ (ppm) 100.9, 117.8, 135.2, 151.2, 156.0. MS m/z: calcd for C18H11N5O5 found 377.07 (M–H): 376.45.

5w: 2-(2-fluorophenyl)-6-(4-nitrophenoxy)-1H-imidazo[4,5-b]pyridine. Yield: 29%. M.P. 140 °C–142 °C. IR v = 1390 cm−1 (c), 1240 cm−1 (C–O ether), 1630, 1840, 1690 cm−1 (aromatic ring), 3310 cm−1 (O–H str) 1H NMR: (600 MHz, DMSO) δ 7.3 (2H, dd, J = 8.3, 1.4 Hz), 7.3–7.5 (3H, m), 7.6 (1H, d, J = 1.7 Hz), 7.9 (1H, dd, J = 7.6, 1.6 Hz), 8.1 (2H, dd, J = 8.3, 2.1 Hz), 8.4 (1H, d, J = 1.7 Hz). 13C NMR (100 MHz, DMSO) δ (ppm) 100.9, 115.0, 130.6, 151.2, 160.4. MS m/z: calcd for C18H11FN4O3 found 350.08 (M–H): 349.53.

Biological evaluation

All synthesised compounds were subjected to anti-tubercular activity against the pathogenic strain for Mycobacterium tuberculosis (H37Rv) ATCC 27294. M. tuberculosis (Mtb) H37Rv ATCC 27294 used for determination of MIC was cultured according to method reported previously by Martin et al. [42]. A single seed lot maintained at − 70 °C was used for obtaining the inoculums for all the experiments. The bacteria was grown in roller bottles containing Middlebrook 7H9 broth supplemented with 0.2% glycerol, 0.05% Tween 80 (Sigma), and 10% albumin dextrose catalase obtained from Difco Laboratories, USA, at 37 °C for 7–10 days. The cell colony was harvested by carrying out centrifugation then it was washed twice in 7H9 broth again it was suspended in fresh 7H9 broth. Several aliquots of 0.5 ml were dispensed and the seed lots of suspension was stored at − 70 °C for further use. To test the viability of prepared culture one of the vial was thawed and plate cultured to determine the colony forming unit (CFU). For compounds 5aw, stock solutions and dilutions were prepared, all test compound stocks and dilutions were prepared in DMSO. Minimum Inhibitory Concentrations (MIC) of all test compounds were determined in Middlebrook 7H9 broth by the standard microdilution method. In a 384 well plate 1 ml of serial two-fold dilutions of test compound was poured in concentration range of 100 µM–0.19 µM. The control wells contained media and culture controls only; Isoniazid was used as standard reference for the assay. As per the reported method, 40 ml (3–7 × 105 CFU/ml) of the bacterial culture was added to all the wells. Only the control wells were devoid of culture. The plates were incubated at 37 °C for 5 days packed in gas permeable polythene bags. After the completion of incubation period, each well was introduced with a freshly prepared 1:1 mixture of Resazurin (0.02% in water), and 10% Tween 80 with 8 ml in quantity. It was understood that change in colour indicates growth or inhibition, if the colour of solution in well changes to blue then it is assumed as inhibition and if changes to pink then growth of the culture. To determine this change all the plates were again incubated for 24 h at 37 °C and then the change in each well was observed. A concentration at which change of colour from blue to pink in inhibited shall be considered as the MIC. Solutions from all the wells were studied for their absorbance at 575 nm and 610 nm then ratio was calculated, an 80% inhibition was considered as MIC. The minimum bactericidal concentration (MBC) is the lowest concentration of an antibacterial agent required to kill the bacteria under study. Aliquots from sample wells (MIC and higher) from the MIC plates were diluted 1:10 and sub cultured on 7H10 agar plates. These were incubated at 37 °C for 3–4 weeks (without test compounds), CFU was studied. The lowest concentration of test compound that resulted in a reduction of about two log10 CFU from the initial unit was considered as MBC.

Molecular docking

Crystal structure of protein (PDB code: 4KW5) was obtained from RCSB protein Data Bank. The receptor molecule was refined using protein preparation wizard module on the maestro molecular modeling interphase, Schrodinger software. Ligands-glycerol, imidazole, FAD and ethyl ({2-[(1,3-benzothiazol-2-ylcarbonyl)amino]thiophen-3-yl}carbonyl)carbamate were already present within the receptor in bound form. All ligands were removed except ethyl ({2-[(1,3-benzothiazol-2-ylcarbonyl)amino]thiophen-3-yl}carbonyl)carbamate to allow for docking protocol [4350]. For this study, all the ligands were prepared and docked for in flexible docking mode and atoms located within a range of 3.0 Å from the amino acid residues were selected in the active site. The docking calculations and energy minimization were set in the ligand docking module, most of the parameters were set default. This cavity consisted of amino acid residues Lys134, Tyr314, Ser228, Lys367, Asn385, Gln336, His132, Val365, Gln334, Cys387, Tyr60, Lys418. This cavity was selected on the basis of reported crystal structure of lead molecule ethyl ({2-[(1,3-benzothiazol-2-yl carboxyl)amino]thiophen-3-yl}carbonyl) carbamate.

Results and discussion


The process of four step sequence was initiated with acetylation of 5,6-diaminopyridine-3-ol 1 on reaction using acetic anhydride to form compound 2. Detail reaction data is not mentioned for this step in the manuscript as this is well known step in organic synthesis. Further, compound 2 was treated with potassium carbonate diluted in dimethyl formamide and latter with p-chloronitrobenzene to form ether linkage 3. The reaction sequence was continued with process of deacetylation by refluxing with 70% sulphuric acid and 10% sodium hydroxide for 20–30 min to obtained compound 4. Compound 4 was treated with various substituted aryl aldehydes to get desired derivatives. Reaction steps were monitored by TLC. Spectroscopic studies were carried out for all the synthesized compounds including intermediates. The IR spectrum showed absorption bands at 1540 cm−1 (N–O str) confirms the presence of nitro group, 1180 cm−1 (C–O str) confirms the ether linkage, bands at 1480 cm−1, 1550 cm−1, 1690 cm−1, 1740 cm−1 indicates the presence of aromatic rings. 1H NMR study displays the protons between δ 7.3 and 8.3 belongs to aromatic ring of imidazopyridine. The 13C NMR studies indicate the aromatic carbons. The compounds were also confirmed by mass analysis.

Molecular docking

The molecular docking study was carried out to uncover the best possible binding modes for newly synthesized derivatives with the enzyme (DprE1). The docking simulations were carried out by Glide docking tool of Maestro molecular modeling interphase (Schrodinger, USA). The receptor employed here was specifically DprE1 (PDB code: 4KW5) obtained from RCSB Protein Data Bank (RCSB-PDB). The initial crystal structure consisted of the bound ligand, it was removed and the missing loops were added. The docking scores of all the compounds were presented in (Table 2). The interacting amino acid residues were identified as Tyr 314, Lyn134, Trp230, Gln 334, Asp389, Phe313, Ser228, Gln312, Lys418, Trp320, Tyr60. The binding modes of the four compounds are presented in (Fig. 1). Imidazopyridine nucleus of compound 5c has shown number of overlaps in pi–pi stacking with Trp230, and Tyr314 also H-bond was observed between nitrogen of pyridine of Imidazopyridine nucleus and Ser228. Both the hydroxyl groups on substituted phenyl ring shows interaction with Gln312. Nitro on phenyl ring connected to Imidazopyridine nucleus by ether linkage shows interaction with Lys418. In compound 5g, nitrogen of Imidazopyridine ring forms hydrogen bond with Ser 228. Tyr314 also shows pi–pi stacking with Imidazopyridine nucleus. Compound 5i emphasizes on interactions of oxygen, proton of nitro group on phenyl ring connected by ether linkage with Trp230, Phe313 respectively where as two oxygen and a proton from nitro group on substituted phenyl ring forms H-bonds with Tyr60, Asp389 and Gln334 respectivey, proton also forms overlapping salt bridge with Asp389. In compound 5u, nitrogen from Imidazopyridine ring forms H-bond with Ser228 and pi–pi stacking with Tyr314, oxygen of phenyl substituted nitro group has shown interaction with Gln 312. Interactions produced by these molecules are quite similar to the lead molecule TCA1, this directs that a substitution with Imidazopyridine nucleus may contribute towards the DprE1 selectivity leading to development of the target specific lead molecules for this series forming potent antitubercular agents.
Table 2

Data of the in vitro studies for M. tuberculosis (H37Rv) and docking score of synthesized compounds

Compound ID

Antitubercular activity MIC (μmol/L) on H37RV

Docking score

Compound ID

Antitubercular activity MIC (μmol/L) on H37RV

Docking score



− 7.234



− 6.964



− 7.140



− 5.761



− 7.500



− 6.657



− 7.400



− 6.193



− 6.695



− 6.186



− 7.081



− 7.084



− 7.698



− 5.793



− 7.286



− 5.761



− 8.825



− 8.213



− 7.611



− 6.657



− 6.685



− 5.836



− 5.761



− 7.328

Fig. 1
Fig. 1

Binding model of compounds 5c, 5g, 5i and 5u with DprE1 target cavity. It represents hydrogen bonds, hydrophobic interactions and pi-pi interactions

Antitubercular activity

In vitro anti-tubercular studies for determination of minimum inhibitory concentration (MIC) and minimal bactericidal concentration (MBC) The in vitro studies were carried out on M. tuberculosis H37Rv (ATCC 27294) strain to determine MIC of test compounds with Isoniazid as standard reference. Microbial culture was developed on Middlebrook 7H9 broth supplemented with 0.2% glycerol, 0.05% Tween 80 (Sigma), and 10% albumin dextrose catalase. The test compounds were prepared as stock and dilutions in DMSO and MIC was determined by microdilution technique. After the incubation period of culture in presence or absence of test compounds, the viability of bacteria was determined by observing the colour change from blue to pink of resazurin mixture which acts as indicator of the inhibitory activity and potency. It was found that compounds 5c, 5g, 5i and 5u exhibited MIC between 0.5 and 0.8 µM which is found very close to the standard reference Isoniazid with MIC of 0.3 µM. The compounds with good MIC were found to be substituted with nitro, methoxy, hydroxyl and halogens like fluorine, chlorine, bromine. Earlier it was reported that nitro group containing compounds inhibit DprE1 selectively due to conversion of the nitro to reduce form and then its interaction with Cys387 residue. Here, we didn’t observed any interaction of synthesized compounds with Cys387 but most of compounds exhibited good docking score with better In vitro antitubercular activity. Furthermore, we have plan to test the compounds with subject to enzyme specific DprE1 inhibitory activity.


We have reported a series of 6-(4-nitrophenoxy)-1H-imidazo[4,5-b]pyridine Derivatives 5aw. Newly synthesized compounds were tested for their In vitro antitubercular activity on the virulent strain H37RV of M. tuberculosis. Few compounds have shown attractive antitubercular activity, among the active compounds, 5c, 5g, 5i and 5v have shown good potency towards M. tuberculosis strain. Molecular docking studies were also carried out using the reported crystal structure of DprE1, we studied flexible binding modes for the synthesized compounds in comparison with the cocrystal reference molecules TCA1 and BTZ043. Interestingly, same compounds (5c, 5g, 5i and 5v) were come up with excellent docking score. Knowledge from the molecular docking studies emphasize that further modifications are also possible in the series of molecules to develop better compounds for potential DprE1 inhibitory activity. Previously, it was reported that nitro group gets reduced and forms adduct with Cys387 to exhibit DprE1 inhibitory activity. Current molecular docking studies strikes on interactions of synthesized chemical structures with various amino acid residues but does not showed any interaction with Cys387 residue but shown excellent docking score. These compounds may exhibit DprE1 inhibitory activity. This information on ligand binding in active site from crystal structure can be utilised for further medicinal chemistry efforts to study enzyme specific inhibition study (Additional file 1).


Authors’ contributions

CB, supervise, designing of synthetic route, molecular docking simulations and other every step of research and reviewed manuscript regularly, suggested corrections, majors for improvisation. JG, conducted laboratory experiments, interpreted the results and wrote the manuscript as a part of his doctoral research. Both authors read and approved the final manuscript.

Competing interests

The authors declare that they have no competing interests.

Availability of data and materials

Not applicable.


No any kind of financial support from National or International Agency was received for the present research work.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (, which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

Department of Pharmaceutical Chemistry, School of Pharmacy & Technology Management, SVKM’s NMIMS, Shirpur Campus, Dhule, 425 405, India


  1. Batt SM, Jabeen T, Bhowruth V, Quill L, Lund PA, Eggeling L (2012) Structural basis of inhibition of Mycobacterium tuberculosis DprE1 by benzothiazinones inhibitors. Proc Natl Acad Sci 109:354–359. View ArticleGoogle Scholar
  2. Riccardi G, Pasca MR, Chiarelli LR, Manina G, Mattevi A, Binda C (2013) The DprE1 enzyme, one of the most vulnerable targets of Mycobacterium tuberculosis. Appl Microbiol Biotechnol 97:8841–8848. View ArticlePubMedGoogle Scholar
  3. Makarov V, Neres J, Hartkoorn RC, Ryabova OB, Kazakova E, Šarkan M (2015) 8-Pyrrole-benzothiazinones non-covalent inhibitors of DprE1 from Mycobacterium tuberculosis. Antimicrob Agents Chemother 59:778–786. View ArticleGoogle Scholar
  4. Scribner A, Dennis R, Lee S, Ouvry G, Perrey D, Fisher M (2008) Synthesis and biological activity of imidazopyridine anticoccidial agents: part II. Eur J Med Chem 43:1123–1151. View ArticlePubMedGoogle Scholar
  5. Piton J, Foo CSY, Cole ST (2017) Structural studies of Mycobacterium tuberculosis DprE1 interacting with its inhibitors. Drug discov today 22:526–533. View ArticlePubMedGoogle Scholar
  6. Foo CSY, Lechartier B, Kolly GS, Boy-Röttger S, Neres J, Rybniker J (2016) Characterization of DprE1-mediated benzothiazinone resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother 60:01523–01537. View ArticleGoogle Scholar
  7. Makarov V, Lechartier B, Zhang M, Neres J, van der Sar AM, Raadsen SA et al (2014) Towards a new combination therapy for tuberculosis with next generation benzothiazinones. EMBO Mol Med. View ArticlePubMedPubMed CentralGoogle Scholar
  8. Neres J, Pojer F, Molteni E, Chiarelli LR, Dhar N, Boy-Röttger S et al (2012) Structural basis for benzothiazinone-mediated killing of Mycobacterium tuberculosis. Sci Transl Med 4:150ra121. View ArticlePubMedPubMed CentralGoogle Scholar
  9. Riccardi G, Pasca MR (2014) Trends in discovery of new drugs for tuberculosis therapy. J Antibiot 67:655–659. View ArticlePubMedGoogle Scholar
  10. Kaminski JJ, Bristol JA, Puchalski C, Lovey RG, Elliott AJ, Guzik H et al (1985) Gastric antisecretory and cytoprotective properties of substituted imidazo[1,2-a]pyridines. J Med Chem 28:876–892. View ArticlePubMedGoogle Scholar
  11. Kaminski JJ, Perkins DG, Frantz JD, Solomon DM, Elliott AJ, Chiu PJS et al (1987) Structure-activity-toxicity relationships of substituted imidazo[1,2-a]pyridines and a related imidazo[1,2-a]pyrazine. J Med Chem 30:2047–2051. View ArticlePubMedGoogle Scholar
  12. Krenitsky TA, Rideout JL, Chao EY, Koszalka GW, Gurney F, Crouch RC et al (1986) Imidazo[4,5-c]pyridines(3-deazapurines) and their nucleosides as immunosuppressive and antiinflammatory agents. J Med Chem 29:138–143. View ArticlePubMedGoogle Scholar
  13. Ramasamy K, Imamura N, Hanna NB, Finch RA, Avery TL, Robins RK et al (1990) Synthesis and antitumor evaluation in mice of certain 7-deazapurine(pyrrolo [2,3-d]pyrimidine) and 3-deazapurine(imidazo[4,5-c]pyridine) nucleosides structurally related to sulfenosine, sulfinosine, and sulfonosine. J Med Chem 33:1220–1225. View ArticlePubMedGoogle Scholar
  14. Temple C Jr, Rose JD, Comber RN, Rener GA (1987) Synthesis of potential anticancer agents: imidazo[4,5-c]pyridines and imidazo[4,5-b]pyridines. J Med Chem 30:1746–1751. View ArticlePubMedGoogle Scholar
  15. Berner H, Reinshagen H, Koch MA (1973) Antiviral. 1. 2-(. alpha.-hydroxybenzyl)imidazo[4,5-c]pyridine. J Med Chem 16:1296–1298. View ArticlePubMedGoogle Scholar
  16. Al-Tel TH, Al-Qawasmeh RA, Zaarour R (2011) Design, synthesis and in vitro antimicrobial evaluation of novel imidazo[1,2-a] pyridine and imidazo [2,1-b][1,3] benzothiazole motifs. Eur J Med Chem 46:1874–1881. View ArticlePubMedGoogle Scholar
  17. Starr JT, Sciotti RJ, Hanna DL, Huband MD, Mullins LM, Cai H et al (2009) 5-(2-Pyrimidinyl)-imidazo [1,2-a] pyridines are antibacterial agents targeting the ATPase domains of DNA gyrase and topoisomerase IV. Bioorg Med Chem Lett 19:5302–5306. View ArticlePubMedGoogle Scholar
  18. Cheng CC, Shipps GW Jr, Yang Z, Sun B, Kawahata N, Soucy KA et al (2009) Discovery and optimization of antibacterial AccC inhibitors. Bioorg Med Chem Lett 19:6507–6514. View ArticlePubMedGoogle Scholar
  19. Bürli RW, Jones P, McMinn D, Le Q, Duan JX, Kaizerman JA et al (2004) DNA binding ligands targeting drug-resistant Gram-positive bacteria. Part 2: C-terminal benzimidazoles and derivatives. Bioorg Med Chem Lett 14:1259–1263. View ArticlePubMedGoogle Scholar
  20. Bishop BC, Chelton ETJ, Jones AS (1964) The antibacterial activity of some fluorine-containing benzimidazoles. Biochem Pharmacol 13:751–754. View ArticlePubMedGoogle Scholar
  21. Dahan-Farkas N, Langley C, Rousseau AL, Yadav DB, Davids H, de Koning CB (2011) 6-Substituted imidazo [1,2-a]pyridines: synthesis and biological activity against colon cancer cell lines HT-29 and Caco-2. Eur J Med Chem 46:4573–4583. View ArticlePubMedGoogle Scholar
  22. Martínez-Urbina MA, Zentella A, Vilchis-Reyes MA, Guzmán Á, Vargas O, Apan MTR et al (2010) 6-Substituted 2-(N-trifluoroacetylamino) imidazopyridines induce cell cycle arrest and apoptosis in SK-LU-1 human cancer cell line. Eur J Med Chem 45:1211–1219. View ArticlePubMedGoogle Scholar
  23. Lhassani M, Chavignon O, Chezal JM, Teulade JC, Chapat JP, Snoeck R et al (1999) Synthesis and antiviral activity of imidazo [1,2-a]pyridines. Eur J Med Chem 34:271–274. View ArticleGoogle Scholar
  24. Mavel S, Renou JL, Galtier C, Allouchi H, Snoeck R, Andrei G et al (2002) Influence of 2-substituent on the activity of imidazo [1,2-a] pyridine derivatives against human cytomegalovirus. Bioorg Med Chem 10:941–946. View ArticlePubMedGoogle Scholar
  25. Hamdouchi C, Ezquerra J, Vega JA, Vaquero JJ, Alvarez-Builla J, Heinz BA (1999) Short synthesis and anti-rhinoviral activity of imidazo [1,2-a] pyridines: the effect of acyl groups at 3-position. Bioorg Med Chem Lett 9:1391–1394. View ArticlePubMedGoogle Scholar
  26. Bode ML, Gravestock D, Moleele SS, van der Westhuyzen CW, Pelly SC, Steenkamp PA et al (2011) Imidazo [1, 2-a] pyridin-3-amines as potential HIV-1 non-nucleoside reverse transcriptase inhibitors. Bioorg Med Chem 19:4227–4237. View ArticlePubMedGoogle Scholar
  27. Robertson DW, Beedle EE, Krushinski JH, Pollock GD, Wilson H, Wyss VL et al (1985) Structure-activity relationships of arylimidazopyridine cardiotonics: discovery and inotropic activity of 2-[2-methoxy-4-(methylsulfinyl) phenyl]-1H-imidazo [4,5-c] pyridine. J Med Chem 28:717–727. View ArticlePubMedGoogle Scholar
  28. Rachakonda V, Alla M, Kotipalli SS, Ummani R (2013) Design, diversity-oriented synthesis and structure activity relationship studies of quinolinyl heterocycles as antimycobacterial agents. Eur J Med Chem 70:536–547. View ArticlePubMedGoogle Scholar
  29. Odell LR, Nilsson MT, Gising J, Lagerlund O, Muthas D, Nordqvist A et al (2009) Functionalized 3-amino-imidazo [1,2-a] pyridines: a novel class of drug-like Mycobacterium tuberculosis glutamine synthetase inhibitors. Bioorg Med Chem Lett 19:4790–4793. View ArticlePubMedGoogle Scholar
  30. Moraski GC, Markley LD, Chang M, Cho S, Franzblau SG, Hwang CH et al (2012) Generation and exploration of new classes of antitubercular agents: the optimization of oxazolines, oxazoles, thiazolines, thiazoles to imidazo [1,2-a] pyridines and isomeric 5,6-fused scaffolds. Bioorg Med Chem 20:2214–2220. View ArticlePubMedPubMed CentralGoogle Scholar
  31. Al-Tel TH, Al-Qawasmeh RA (2010) Post Groebke-Blackburn multicomponent protocol: synthesis of new polyfunctional imidazo [1,2-a] pyridine and imidazo [1,2-a] pyrimidine derivatives as potential antimicrobial agents. Eur J Med Chem 45:5848–5855. View ArticlePubMedGoogle Scholar
  32. Pethe K, Bifani P, Jang J, Kang S, Park S, Ahn S et al (2013) Discovery of Q203, a potent clinical candidate for the treatment of tuberculosis. Nat Med 19:1157–1160. View ArticlePubMedGoogle Scholar
  33. Véron JB, Allouchi H, Enguehard-Gueiffier C, Snoeck R, Andrei G, De Clercq E, Gueiffier A (2008) Influence of 6-or 8-substitution on the antiviral activity of 3-arylalkylthiomethylimidazo [1,2-a] pyridine against human cytomegalovirus (CMV) and varicella-zoster virus (VZV): part II. Bioorg Med Chem 16:9536–9545. View ArticlePubMedGoogle Scholar
  34. Bochis RJ, Dybas RA, Eskola P, Kulsa P, Linn BO, Lusi A (1978) Methyl 6-(phenylsulfinyl) imidazo [1,2-a] pyridine-2-carbamate, a potent, new anthelmintic. J Med Chem 21:235–237. View ArticlePubMedGoogle Scholar
  35. Taha M, Ismail NH, Imran S, Rashwan H, Jamil W, Ali S et al (2016) Synthesis of 6-chloro-2-aryl-1H-imidazo [4, 5-b] pyridine derivatives: antidiabetic, antioxidant, β-glucuronidase inhibiton and their molecular docking studies. Bioorg Chem 65:48–56. View ArticlePubMedGoogle Scholar
  36. Zamora R, Hidalgo FJ (2015) 2-Amino-1-methyl-6-phenylimidazo [4,5-b] pyridine (PhIP) formation and fate: an example of the coordinate contribution of lipid oxidation and Maillard reaction to the production and elimination of processing-related food toxicants. RSC Adv 5:9709–9721. View ArticleGoogle Scholar
  37. Huang H, Dang P, Wu L, Liang Y, Liu J (2016) Copper-catalyzed synthesis of benzo [b] thiophene-fused imidazopyridines via the cleavage of C–H bond and C–X bond. Tetrahedron Lett 57:574–577. View ArticleGoogle Scholar
  38. Jana S, Chakraborty A, Shirinian VZ, Hajra A (2018) Synthesis of Benzo [4,5] imidazo [2,1-b] thiazole by copper (II)-catalyzed thioamination of nitroalkene with 1H-benzo [d] imidazole-2-thiol. Adv Synth Catal 360:2402–2408. View ArticleGoogle Scholar
  39. Wang Y, Fu H, Li Y, Jiang J, Song D (2012) Synthesis and biological evaluation of 8-substituted berberine derivatives as novel anti-mycobacterial agents. Acta Pharm Sin B 2:581–587. View ArticleGoogle Scholar
  40. Li Y, Liu Y, Wang Y, Tang S, Song D (2013) Synthesis and biological evaluation of new 13-n-nonylprotoberberine derivatives as antitubercular agents. Acta Pharm Sin B 3:38–45. View ArticleGoogle Scholar
  41. Cai Q, Liu MC, Mao BM, Xie X, Jia FC, Zhu YP et al (2015) Direct one-pot synthesis of zolimidine pharmaceutical drug and imidazo [1,2-a] pyridine derivatives via I2/CuO-promoted tandem strategy. Chin Chem Lett 26:881–884. View ArticleGoogle Scholar
  42. Martin A, Palomino JC. Resazurin Microtiter Assay (REMA): Resazurin Microtitre assay (REMA) Colorimetric redox indicator (CRI). Drug susceptibility testing for Mycobacterium tuberculosis, Institute of Tropical Medicine, Belgium. Procedure Manual Version, 3. 2009Google Scholar
  43. Schrodinger L.L.C. (2012) Schrodinger suite 2012 induced fit docking protocol; glide version 58. Schrodinger LLC., New YorkGoogle Scholar
  44. Shirude PS, Shandil R, Sadler C, Naik M, Hosagrahara V, Hameed S et al (2013) Azaindoles: noncovalent DprE1 inhibitors from scaffold morphing efforts, kill Mycobacterium tuberculosis and are efficacious in vivo. J Med Chem 56:9701–9708. View ArticlePubMedGoogle Scholar
  45. Panda M, Ramachandran S, Ramachandran V, Shirude PS, Humnabadkar V, Nagalapur K et al (2014) Discovery of pyrazolopyridones as a novel class of noncovalent DprE1 inhibitor with potent anti-mycobacterial activity. J Med Chem 57:4761–4771. View ArticlePubMedGoogle Scholar
  46. Trefzer C, Rengifo-Gonzalez M, Hinner MJ, Schneider P, Makarov V, Cole ST et al (2010) Benzothiazinones: prodrugs that covalently modify the decaprenylphosphoryl-β-d-ribose 2′-epimerase DprE1 of Mycobacterium tuberculosis. J Am Chem Soc 132:13663–13665. View ArticlePubMedGoogle Scholar
  47. Neres J, Hartkoorn RC, Chiarelli LR, Gadupudi R, Pasca MR, Mori G et al (2014) 2-Carboxyquinoxalines kill Mycobacterium tuberculosis through noncovalent inhibition of DprE1. ACS Chem Biol 10:705–714. View ArticlePubMedGoogle Scholar
  48. Mori G, Chiarelli LR, Riccardi G, Pasca MR (2017) New prodrugs against tuberculosis. Drug Discov Today 22:519–525. View ArticlePubMedGoogle Scholar
  49. He JL, Xie JP (2011) Advances in mycobacterium siderophore-based drug discovery. Acta Pharm Sin B 1:8–13. View ArticleGoogle Scholar
  50. Wang P, Pradhan K, Zhong XB, Ma X (2016) Isoniazid metabolism and hepatotoxicity. Acta Pharm Sin B 6:384–392. View ArticlePubMedPubMed CentralGoogle Scholar


© The Author(s) 2018